1 |
FDA guidance for industry, SUPAC-MR: modified release solid oral dosage forms; scale-up and post approval changes; chemistry, manufacturing and controls; In vitro dissolution testing and in vivo bioequivalence documentation, September, 32-33 (1997)
|
2 |
The pharmacopeia of the United States, 26th Rev., the United States pharmacopeial convention, Inc., Rockville, MD, USA, 2355-2356, 2003
|
3 |
S.W. Lee, S.H. Kam, J.W. Hong, K.S. Choi, E.S. Park and S.C. Chi, Effect of poloxamer content on dissolution of diltiazem hydrochloride from core pellets. J. Kor. Pharm. Sci., 32(4), 305-311 (2002)
|
4 |
P.C. Wu, Y.B. Huang, J.I. Chang, M.J. Tsai and Y.H. Tsai, Preparation and evaluation of sustained release microspheres of potassium chloride prepared with ethylcellulose, Int. J. Pharm., 260, 115-121 (2003)
DOI
ScienceOn
|
5 |
Y.H, Lee, K.B. Shim, M.H. Lee and S.K. Kim, HPLC determination of diltiazem and deacetyldiltiazem in rat plasma, J. Kor. Pharm. Sci., 22(4),317-321 (1992)
|
6 |
The pharmacopeia of the Japan, 14th rev. Hirakawa, Tokyo, C674-C677 (2001)
|
7 |
B.S. Rao and K.Y.R. Murthy, Studies on rifampicin release from ethylcellulose coated nonpareil beads, Int. J. Pharm., 231,97-106 (2002)
DOI
ScienceOn
|
8 |
M. Choi, C.S. Kang, B.K. Choi, C.H. Hong and K.S. Kim, In vitro/in vivo correlation of sustained release diltiazem, J. Kor. Pharm. Sci., 32(4), 321-325 (2002)
|
9 |
H. Kim and R. Fassibi, A ternary polymeric matrix system for controlled drug delivery of highly soluble drug with high drug loading: diltiazem hydrochloride, J. Kor. Pharm. Sci., 31(1), 19-25 (2001)
|